RE:RE:RE:RE:RE:Re: Up 39.39% in one week"the point being czo is not in the business of acquiring assets albeit it be good or not it's business is to develop the pgx technology applications"
That CZO is building a biopharma has been a very consistent message for a very long time. Avenanthramide is in clinical trials now. Fibrosis appears nearning clinical trials. Wound healing could also be on the verge of clinical trials. The 5X PGX facility expected to be commissioned this month will provide clinical materials. PGX produces delivery systems and PGX-YBG could be a Trojan Horse to deliver other drugs/bioactives. PGX-YBG could be inhalable allowing other drugs to be delivered. Alginate is a recognized drug delivery vehicle and CZO has enhanced its carrying capacity. The opportunities are endless and likely why someone like Ronnie Miller is attracted to the opportunity. Biotech gets very capital intensive moving forward. CZO's base business isn't going to be enough. Avalyn raised C$80 million going into its Phase I fibrosis trial and CZO is much more than just fibrosis. Moving to NASDAQ is a next step to help secure capital. AEZS provides capital, and human resources as CZO's clinical trial activity potentially accelerates. AEZS also has additional opportuntiies as CZO build a biopharma and CZO could acquire tham below cash as the biotech market turns.